PMID- 22695966
OWN - NLM
STAT- MEDLINE
DCOM- 20121106
LR  - 20131121
IS  - 1552-5783 (Electronic)
IS  - 0146-0404 (Linking)
VI  - 53
IP  - 9
DP  - 2012 Aug 3
TI  - Toxicity evaluation of antiglaucoma drugs using stratified human cultivated 
      corneal epithelial sheets.
PG  - 5154-60
LID - 10.1167/iovs.12-9685 [doi]
AB  - PURPOSE: To investigate the toxicity profiles of seven antiglaucoma topical eye 
      drops and benzalkonium chloride (BAC) using stratified cultivated human corneal 
      epithelial cell sheets (HCES) in a serum-free culture system. METHODS: A range of 
      prostaglandin analogies and preservatives, including BAC, sofZia (SZ), sodium 
      benzoate (SB), and polyquaternium-1 (PQ) were tested. The barrier function and 
      cell viability were examined by a carboxyfluorescein permeability assay and WST-1 
      assay. Histological evaluation of the HCES was also performed after application 
      of each solution. RESULTS: The carboxyfluorescein permeability assay had a higher 
      sensitivity for the detection of toxicity of test solutions than the WST-1 assay 
      or histological examination. Latanoprost BAC, latanoprost/timolol BAC, and 0.02% 
      or higher concentration of BAC were the most toxic, followed by latanoprost SB, 
      latanoprost preservative-free, BAC 0.002%, and travoprost/ latanoprost PQ. 
      Travoprost SZ and tafluprost BAC (preserved with 0.001% BAC) was the least toxic 
      in our experimental conditions. CONCLUSIONS: The carboxyfluorescein permeability 
      assay using HCES in a serum-free system was the most useful for the 
      quantification of toxicity of ophthalmic solutions. Among the regimens examined, 
      a BAC concentration of 0.001% or lower or non-BAC preservative sofZia was 
      suggested to be the least toxic to the ocular surface.
FAU - Nakagawa, Suguru
AU  - Nakagawa S
AD  - Department of Ophthalmology, University of Tokyo School of Medicine, Tokyo, 
      Japan.
FAU - Usui, Tomohiko
AU  - Usui T
FAU - Yokoo, Seiichi
AU  - Yokoo S
FAU - Omichi, Sachiko
AU  - Omichi S
FAU - Kimakura, Mikiko
AU  - Kimakura M
FAU - Mori, Yosai
AU  - Mori Y
FAU - Miyata, Kazunori
AU  - Miyata K
FAU - Aihara, Makoto
AU  - Aihara M
FAU - Amano, Shiro
AU  - Amano S
FAU - Araie, Makoto
AU  - Araie M
LA  - eng
PT  - Journal Article
DEP - 20120803
PL  - United States
TA  - Invest Ophthalmol Vis Sci
JT  - Investigative ophthalmology & visual science
JID - 7703701
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Benzalkonium Compounds)
RN  - 0 (Culture Media, Serum-Free)
RN  - 0 (Drug Combinations)
RN  - 0 (Fluoresceins)
RN  - 0 (Fluorescent Dyes)
RN  - 0 (Membrane Proteins)
RN  - 0 (Ophthalmic Solutions)
RN  - 0 (Phosphoproteins)
RN  - 0 (Preservatives, Pharmaceutical)
RN  - 0 (Prostaglandins F, Synthetic)
RN  - 0 (TJP1 protein, human)
RN  - 0 (Zonula Occludens-1 Protein)
RN  - 3301-79-9 (6-carboxyfluorescein)
RN  - 817W3C6175 (Timolol)
SB  - IM
MH  - Antihypertensive Agents/*toxicity
MH  - Benzalkonium Compounds/toxicity
MH  - Cell Membrane Permeability
MH  - Cell Survival
MH  - Cells, Cultured
MH  - Culture Media, Serum-Free
MH  - Drug Combinations
MH  - Epithelium, Corneal/*drug effects
MH  - Fluoresceins/metabolism
MH  - Fluorescent Dyes/metabolism
MH  - Glaucoma/drug therapy
MH  - Humans
MH  - Membrane Proteins/metabolism
MH  - Ophthalmic Solutions/toxicity
MH  - Phosphoproteins/metabolism
MH  - Preservatives, Pharmaceutical/toxicity
MH  - Prostaglandins F, Synthetic/toxicity
MH  - Timolol/toxicity
MH  - Zonula Occludens-1 Protein
EDAT- 2012/06/15 06:00
MHDA- 2012/11/07 06:00
CRDT- 2012/06/15 06:00
PHST- 2012/06/15 06:00 [entrez]
PHST- 2012/06/15 06:00 [pubmed]
PHST- 2012/11/07 06:00 [medline]
AID - iovs.12-9685 [pii]
AID - 10.1167/iovs.12-9685 [doi]
PST - epublish
SO  - Invest Ophthalmol Vis Sci. 2012 Aug 3;53(9):5154-60. doi: 10.1167/iovs.12-9685.